Article (Scientific journals)
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Laharie, David; D'Haens, Geert; Nachury, Maria et al.
2022In Clinical Gastroenterology and Hepatology, 20 (9), p. 2074-2082
Peer Reviewed verified by ORBi


Full Text
Author postprint (593.36 kB)

All documents in ORBi are protected by a user license.

Send to


Keywords :
Steroids; B72HH48FLU (Infliximab); Crohn Disease; Disease Progression; Follow-Up Studies; Humans; Infliximab; Prospective Studies; Remission Induction; Treatment Outcome; Crohn’s Disease; Deep Remission; Endoscopic Remission
Abstract :
[en] BACKGROUND & AIMS: Crohn's disease (CD) patients included in the Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) trial started infliximab in combination with an immunosuppressant for 1 year. The aim of the present study was to determine the long-term disease course beyond the study period. METHODS: We compared the outcomes of patients who did or did not reach the primary end point of the TAILORIX trial, defined as sustained corticosteroid-free clinical remission from weeks 22 through 54, with no ulcers on ileocolonoscopy at week 54. The primary outcome of this follow-up study was the progression-free survival of CD defined by anal or major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment. RESULTS: The 95 patients (median disease duration, 4.5 mo; interquartile range, 1.0-56.6 mo) analyzed, including 45 (47%) who achieved the primary end point, were followed up for a median duration of 64.2 months (interquartile range, 57.6-69.9 mo) after the end of the study period. There was no significant difference in CD progression-free survival at 1, 3, and 5 years between patients who achieved the TAILORIX primary end point and patients who did not (P = .64). No difference was observed between both groups for each component of CD progression: anal surgery, major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment. CONCLUSIONS: Achieving a sustained clinical remission off steroids with complete endoscopic remission in this cohort of 95 patients with early CD was not associated with less disease progression. Prospective trials to define the therapeutic goals that change the natural history of CD and prevent complications are needed.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Laharie, David;  Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, Service
D'Haens, Geert;  Hepato-Gastroenterology Department, Amsterdam University Medical Centers,
Nachury, Maria;  Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille,
Lambrecht, Guy;  Gastroenterology Unit, Damiaan Hospital, Oostende, Belgium.
Bossuyt, Peter;  Imelda Gastronintestinal Clinical Research Center, Department of
Bouhnik, Yoram;  Hepato-Gastroenterology Department, Beaujon Hospital.
Louis, Edouard  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Janneke van der Woude, Christien;  Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The
Buisson, Anthony;  Hepato-Gastroenterology Department, Hospital Estaing, Clermont-Ferrand, France.
Van Hootegem, Philippe;  Department of Gastroenterology, Sint-Lucas General Hospital, Brugge, Belgium.
Allez, Matthieu;  Hepato-Gastroenterology Department, Saint-Louis Hospital, University of Paris
Filippi, Jérôme;  Department of Gastroenterology, Hôpital L'Archet, Nice, France.
Brixi, Hedia;  CHU Robert Debré, Service d'Hépato-gastroentérologie et Oncologie Digestive,
Gilletta, Cyrielle;  Department of Gastroenterology and Pancreatology, CHU de Toulouse, Toulouse,
Picon, Laurence;  Department of Gastroenterology, Centre Hospitalier Regional Universitaire de
Baert, Filip;  AZ Delta, Roeselare, Belgium.
Vermeire, Séverine;  University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.
Duveau, Nicolas;  Hepato-Gastroenterology Department, Roubaix Hospital, Roubaix, France.
Peyrin-Biroulet, Laurent;  Department of Gastroenterology, Inserm U1256, Nancy University Hospital, Lorraine
More authors (9 more) Less
Language :
Title :
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Publication date :
September 2022
Journal title :
Clinical Gastroenterology and Hepatology
Publisher :
W. B. Saunders Co., Gb
Volume :
Issue :
Pages :
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Janssen Pharmaceutica [BE]
MSD - Merck Sharp and Dohme [BE]
Data Set :

© 2022 by the AGA Institute 1542-3565/$36.00

Commentary :
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.
Available on ORBi :
since 02 March 2023


Number of views
91 (1 by ULiège)
Number of downloads
106 (0 by ULiège)

Scopus citations®
Scopus citations®
without self-citations


Similar publications

Contact ORBi